Jane Street
TEVA icon

Jane Street’s Teva Pharmaceuticals TEVA Stock Holding History

Jane Street’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.9M Sell
1,158,400
-4,756,600
-80% -$153M ﹤0.01% 1307
2025
Q4 		$185M Buy
5,915,000
+542,300
+10% +$13.4M 0.03% 379
2025
Q3 		$109M Sell
5,372,700
-180,300
-3% -$3.17M 0.02% 558
2025
Q2 		$93.1M Buy
5,553,000
+1,817,000
+49% +$29.3M 0.02% 492
2025
Q1 		$57.4M Buy
3,736,000
+1,138,600
+44% +$20.3M 0.01% 599
2024
Q4 		$57.2M Buy
2,597,400
+917,500
+55% +$16.7M 0.01% 631
2024
Q3 		$30.3M Sell
1,679,900
-550,800
-25% -$9.64M 0.01% 973
2024
Q2 		$36.2M Buy
2,230,700
+930,700
+72% +$14.3M 0.01% 871
2024
Q1 		$18.3M Buy
1,300,000
+496,600
+62% +$6.26M ﹤0.01% 1259
2023
Q4 		$8.39M Sell
803,400
-528,100
-40% -$4.93M ﹤0.01% 2169
2023
Q3 		$13.6M Buy
1,331,500
+682,800
+105% +$6.36M ﹤0.01% 1451
2023
Q2 		$4.88M Buy
648,700
+294,600
+83% +$2.39M ﹤0.01% 2772
2023
Q1 		$3.13M Sell
354,100
-1,923,500
-84% -$19M ﹤0.01% 3082
2022
Q4 		$20.8M Sell
2,277,600
-157,800
-6% -$1.38M 0.01% 975
2022
Q3 		$19.7M Sell
2,435,400
-353,200
-13% -$3.12M 0.01% 1086
2022
Q2 		$21M Buy
2,788,600
+1,009,800
+57% +$8.8M 0.01% 1087
2022
Q1 		$16.7M Buy
1,778,800
+598,400
+51% +$4.99M 0.01% 1429
2021
Q4 		$9.46M Sell
1,180,400
-1,117,100
-49% -$10.1M ﹤0.01% 1947
2021
Q3 		$22.4M Buy
2,297,500
+502,200
+28% +$4.7M 0.01% 1063
2021
Q2 		$17.8M Buy
1,795,300
+701,500
+64% +$7.43M 0.01% 1173
2021
Q1 		$12.6M Buy
1,093,800
+231,000
+27% +$2.65M 0.01% 1337
2020
Q4 		$8.33M Buy
862,800
+161,800
+23% +$1.55M ﹤0.01% 1580
2020
Q3 		$6.32M Sell
701,000
-805,300
-53% -$8.52M ﹤0.01% 1620
2020
Q2 		$18.6M Buy
1,506,300
+904,800
+150% +$10.2M 0.01% 796
2020
Q1 		$5.4M Buy
601,500
+350,200
+139% +$3.59M 0.01% 1130
2019
Q4 		$2.46M Buy
251,300
+114,700
+84% +$1.02M ﹤0.01% 1712
2019
Q3 		$940K Sell
136,600
-129,100
-49% -$989K ﹤0.01% 2699
2019
Q2 		$2.45M Buy
265,700
+120,900
+83% +$1.46M ﹤0.01% 1682
2019
Q1 		$2.27M Sell
144,800
-2,004,800
-93% -$35.4M ﹤0.01% 1905
2018
Q4 		$33.1M Buy
2,149,600
+1,799,900
+515% +$36.9M 0.07% 193
2018
Q3 		$7.53M Buy
349,700
+130,600
+60% +$3.03M 0.01% 779
2018
Q2 		$5.33M Buy
219,100
+98,300
+81% +$2M 0.01% 984
2018
Q1 		$2.06M Sell
120,800
-153,400
-56% -$3M 0.01% 1818
2017
Q4 		$5.2M Buy
274,200
+199,200
+266% +$3M 0.01% 853
2017
Q3 		$1.32M Buy
75,000
+47,000
+168% +$1.06M ﹤0.01% 2008
2017
Q2 		$930K Sell
28,000
-14,000
-33% -$433K ﹤0.01% 2297
2017
Q1 		$1.35M Buy
42,000
+800
+2% +$27.3K 0.01% 1745
2016
Q4 		$1.49M Buy
41,200
+31,100
+308% +$1.24M 0.01% 1588
2016
Q3 		$465K Buy
10,100
+700
+7% +$36.5K ﹤0.01% 2846
2016
Q2 		$472K Sell
9,400
-35,300
-79% -$1.88M ﹤0.01% 2818
2016
Q1 		$2.39M Sell
44,700
-31,800
-42% -$1.87M 0.01% 1028
2015
Q4 		$5.02M Buy
76,500
+17,100
+29% +$1.06M 0.03% 488
2015
Q3 		$3.35M Buy
+59,400
New +$3.85M 0.02% 627
2015
Q2 		– Sell
-36,000
Closed -$2.24M – 4038
2015
Q1 		$2.24M Buy
+36,000
New +$2.09M 0.02% 784

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's TEVA Position: Q1 2026 in Review

Jane Street reduced its Teva Pharmaceuticals (TEVA) stake by 9.5% in Q1 2026, selling an estimated $4.96M and leaving 1,464,638 shares worth $44.1M. The position accounts for 0.01% of the portfolio, ranked #1147.

Jane Street first reported a position in TEVA in Q4 2013 and has held it in 49 quarters since. The position peaked at $60.7M in Q3 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Jane Street held 1,464,638 shares of Teva Pharmaceuticals worth $44.1M as of Q1 2026.
  • Jane Street sold 154,241 Teva Pharmaceuticals shares in Q1 2026, an estimated $4.96M.
  • Teva Pharmaceuticals made up 0.01% of Jane Street's portfolio in Q1 2026, its #1147 holding.
  • Jane Street first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
  • Jane Street's Teva Pharmaceuticals position peaked at $60.7M in Q3 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.